Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 8/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295757 | 0.84 | F11 (0.46) | GAAMAPK1NPC1F11KLK1 | |
| SCHEMBL19278111 | 0.83 | LNPEP (0.57) | LNPEPERAP2MAPTGAAMAPK1 | |
| SCHEMBL19874085 | 0.81 | F11 (0.45) | MAPK1NPC1RAB9AF11KLK1 | |
| SCHEMBL17295708 | 0.76 | RAB9A (0.51) | MAPTGAANPC1RAB9AF11 | |
| SCHEMBL17477804 | 0.76 | LNPEP (0.57) | LNPEPERAP2KDM4EKMT2A | |
| SCHEMBL19886605 | 0.76 | F11 (0.44) | AAK1NPC1RAB9AF11KLK1 | |
| SCHEMBL17295685 | 0.75 | F11 (0.56) | F11KLK1 | |
| SCHEMBL17295745 | 0.75 | RAB9A (0.39) | AAK1NPC1RAB9AALDH1A1 | |
| SCHEMBL17480676 | 0.75 | LNPEP (0.47) | AAK1LNPEPERAP2ALOX15 | |
| SCHEMBL17295770 | 0.72 | CPB2 (0.42) | NPC1RAB9AF11KLK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180327-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3180327-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10011585-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011585-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170240523-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240523-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240523-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3180327-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016018701-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016018701-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240523-A1 | FACTOR XIa INHIBITORS | F11, SERPINC1, TFPI | AAK1 1521/4885LNPEP 1610/4885ERAP2 1507/4885 |
| US-10011585-B2 | Factor XIa inhibitors | F11, SERPINC1, TFPI | AAK1 1521/4885LNPEP 1610/4885ERAP2 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.